| CTRI Number |
CTRI/2025/09/095126 [Registered on: 19/09/2025] Trial Registered Prospectively |
| Last Modified On: |
19/09/2025 |
| Post Graduate Thesis |
Yes |
| Type of Trial |
Interventional |
|
Type of Study
|
Drug |
| Study Design |
Randomized, Parallel Group, Placebo Controlled Trial |
|
Public Title of Study
|
MITOCHONDRIAL
SUPPLEMENTATION IMPACT ON RESOLUTION OF PEDIATRIC SEPTIC SHOCK |
|
Scientific Title of Study
|
IMPACT OF MITOCHONDRIAL
SUPPLEMENTATION ON RESOLUTION OF
PEDIATRIC SEPTIC SHOCK: A PROSPECTIVE
RANDOMIZED CONTROL TRIAL |
| Trial Acronym |
NIL |
|
Secondary IDs if Any
|
| Secondary ID |
Identifier |
| NIL |
NIL |
|
|
Details of Principal Investigator or overall Trial Coordinator (multi-center study)
|
| Name |
Srijan Sinha |
| Designation |
Senior Resident (ACADEMIC) |
| Affiliation |
AIIMS RISHIKESH |
| Address |
PICU, Department of Pediatrics, AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, DEHRADUN, UK 249203
Dehradun UTTARANCHAL 249203 India |
| Phone |
9546884678 |
| Fax |
|
| Email |
AIIMSJ15@GMAIL.COM |
|
Details of Contact Person Scientific Query
|
| Name |
Lokesh Tiwari |
| Designation |
Professor |
| Affiliation |
AIIMS RISHIKESH |
| Address |
PICU, Department of Pediatrics, AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, DEHRADUN, UK 249203
Dehradun UTTARANCHAL 249203 India |
| Phone |
9631638095 |
| Fax |
|
| Email |
LOKESHDOC@YAHOO.COM |
|
Details of Contact Person Public Query
|
| Name |
Srijan Sinha |
| Designation |
Senior Resident |
| Affiliation |
AIIMS RISHIKESH |
| Address |
PICU, Department of Pediatrics, AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, DEHRADUN, UK 249203
Dehradun UTTARANCHAL 249203 India |
| Phone |
9546884678 |
| Fax |
|
| Email |
AIIMSJ15@GMAIL.COM |
|
|
Source of Monetary or Material Support
|
|
|
Primary Sponsor
|
| Name |
AIIMS RISHIKESH |
| Address |
AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, DEHRADUN DISTRICT, UTTARAKHAND, INDIA. 249203 |
| Type of Sponsor |
Government medical college |
|
|
Details of Secondary Sponsor
|
|
|
Countries of Recruitment
|
India |
|
Sites of Study
|
| No of Sites = 1 |
| Name of Principal
Investigator |
Name of Site |
Site Address |
Phone/Fax/Email |
| DR SRIJAN SINHA |
AIIMS RISHIKESH |
PICU, Department of Pediatrics, AIIMS RISHIKESH, VIRBHADRA ROAD, RISHIKESH, UK Dehradun UTTARANCHAL |
9546884678
SRIJANSINHA2@GMAIL.COM |
|
|
Details of Ethics Committee
|
| No of Ethics Committees= 1 |
| Name of Committee |
Approval Status |
| AIIMS RISHIKESH |
Approved |
|
|
Regulatory Clearance Status from DCGI
|
|
|
Health Condition / Problems Studied
|
| Health Type |
Condition |
| Patients |
(1) ICD-10 Condition: R652||Severe sepsis, |
|
|
Intervention / Comparator Agent
|
| Type |
Name |
Details |
| Intervention |
Mitochondrial Supplementation |
Thiamin
Vitamin C
Vitamin E
Carnitine
Coenzyme Q
Hydrocortisone |
| Comparator Agent |
NIL |
NIL |
|
|
Inclusion Criteria
|
| Age From |
1.00 Month(s) |
| Age To |
18.00 Year(s) |
| Gender |
Both |
| Details |
Children aged 1 months to 18 years with septic shock, defined as children with suspect or confirmed sepsis and cardiovascular dysfunction as per Phoenix Sepsis Score |
|
| ExclusionCriteria |
| Details |
Children who require Nil per oral status
Children with known HIV/HbSAg/HCV positive status
Children with confirmed Immunodeficiency
Children with malignancy
Children who are known cases of G6PD deficiency/ Oxalate nephropathy
|
|
|
Method of Generating Random Sequence
|
Computer generated randomization |
|
Method of Concealment
|
Sequentially numbered, sealed, opaque envelopes |
|
Blinding/Masking
|
Open Label |
|
Primary Outcome
|
| Outcome |
TimePoints |
| Comparison on median VIS score (Vasoactive inotrope score) during 1st 3 days after initiation of therapy. |
Comparison on median VIS score (Vasoactive inotrope score) during 1st 3 days after initiation of therapy. |
|
|
Secondary Outcome
|
| Outcome |
TimePoints |
Survival status at Day 3, Day 7, and Day 28 following initiation of mitochondrial supplementation in pediatric patients with septic shock.
Maximum vasoactive-inotropic score (VIS) on Days 5 and 7
Trend in Pediatric Sequential Organ Failure Assessment (pSOFA) scores from admission through Day 7 or until PICU discharge, whichever occurs earlier.
Ventilation-free days and Inotrope-free days within the first 28 days. |
3, 7, 28 DAYS |
|
|
Target Sample Size
|
Total Sample Size="160" Sample Size from India="160"
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" |
|
Phase of Trial
|
Phase 4 |
|
Date of First Enrollment (India)
|
01/12/2025 |
| Date of Study Completion (India) |
Applicable only for Completed/Terminated trials |
| Date of First Enrollment (Global) |
Date Missing |
| Date of Study Completion (Global) |
Applicable only for Completed/Terminated trials |
|
Estimated Duration of Trial
|
Years="1" Months="6" Days="0" |
|
Recruitment Status of Trial (Global)
|
Not Yet Recruiting |
| Recruitment Status of Trial (India) |
Not Yet Recruiting |
|
Publication Details
|
N/A |
|
Individual Participant Data (IPD) Sharing Statement
|
Will individual participant data (IPD) be shared publicly (including data dictionaries)?
Response - YES
- What data in particular will be shared?
Response - All of the individual participant data collected during the trial, after de-identification.
- What additional supporting information will be shared?
Response - Study Protocol Response - Statistical Analysis Plan Response - Informed Consent Form Response - Clinical Study Report Response - Analytic Code
- Who will be able to view these files?
Response - Researchers whose proposed use of the data has been approved by an independent review committee identified for this purpose.
- For what types of analyses will this data be available?
Response - For individual participant data meta-analysis.
- By what mechanism will data be made available?
Response - Proposals should be directed to [SRIJANSINHA2@GMAIL.COM].
- For how long will this data be available start date provided 01-01-2028 and end date provided 31-12-2030?
Response - Beginning 3 months and ending 5 years following article publication.
- Any URL or additional information regarding plan/policy for sharing IPD?
Additional Information - NIL
|
|
Brief Summary
|
Shock in children results from varied causes, hypovolemic and septic shock being the most common causes. Pediatric septic shock results due to inflammatory response to a focus of infection. In sepsis, there is release of various cytokines which results in increased capillary permeability and myocardial dysfunction. The early manifestations of shock in children include tachycardia, cold peripheries, prolonged CFT, narrow pulse pressure and late signs include altered mental status and hypotension. Early recognition of shock and early interventions are associated with favourable outcomes. Metabolic supplementation refers to a therapeutic strategy aimed at correcting the underlying metabolic derangements that occur during critical illness, particularly in conditions such as sepsis, septic shock, multi-organ dysfunction, and acute kidney injury (AKI). During severe illness, multiple metabolic pathways become dysregulated, including impaired cellular energy production, mitochondrial dysfunction, oxidative stress, hormonal disturbances, and dysregulated immune responses. These disturbances can further perpetuate organ dysfunction, making targeted metabolic support an important adjunct to conventional resuscitation strategies. The cornerstone of metabolic resuscitation involves the administration of key micronutrients and metabolic cofactors that support mitochondrial function, reduce oxidative stress, and modulate inflammation. One of the most studied regimens is the combination of intravenous Vitamin C, hydrocortisone, and thiamine. Vitamin C acts as a potent antioxidant and cofactor for catecholamine synthesis; thiamine supports mitochondrial oxidative metabolism and prevents lactic acidosis; while hydrocortisone helps restore vascular responsiveness and modulate the exaggerated inflammatory response.
Mitochondrial supplementation represents an emerging therapeutic approach aimed at restoring mitochondrial function in critically ill patients, where mitochondrial dysfunction is increasingly recognized as a central contributor to multi-organ failure. Mitochondria play a pivotal role in energy production, regulation of oxidative stress, calcium homeostasis, and apoptosis. In conditions such as sepsis, ischemia-reperfusion injury, acute kidney injury, cardiac arrest, and neurodegenerative disorders, mitochondrial injury leads to impaired oxidative phosphorylation, excessive generation of reactive oxygen species (ROS), mitochondrial membrane permeability transition pore (mPTP) opening, calcium dysregulation, and activation of intrinsic apoptotic pathways. These processes collectively result in bioenergetic failure, cellular dysfunction, and organ injury. Therapeutic strategies for mitochondrial supplementation include the administration of systemic and mitochondria-targeted antioxidants and metabolic cofactors (e.g., Coenzyme Q10, L-carnitine) and agents that stimulate mitochondrial biogenesis. Given the central role of impaired perfusion, systemic inflammation, and metabolic dysregulation in pediatric shock and AKI, there is a growing interest in adjunctive therapies targeting mitochondrial health and cellular energetics. This trial aims to explore its role in pediatric septic shock as an adjunct to standard of care. |